Protagonist Therapeutics, Inc. — Q1 2018 Form 10-Q Summary
Business context and reporting period
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing constrained peptide-based therapies. The filing covers the three months ended March 31, 2018, and was filed May 9, 2018. The company had no approved products or product sales and operated as a single segment.
- PTG-100: Global Phase 2b ulcerative colitis trial was discontinued in March 2018 after an independent Data Monitoring Committee determined that the interim efficacy analysis met pre-specified futility criteria. No safety concerns were identified.
- PTG-200: Oral IL-23 receptor antagonist in a Phase 1 healthy-volunteer study; the company expected to file a U.S. IND and other regulatory submissions in the second half of 2018 for a global Phase 2 Crohn’s disease study with Janssen.
- PTG-300: Injectable hepcidin mimetic; Phase 1 was completed in late 2017, and the FDA granted orphan drug designation for beta-thalassemia in March 2018. The company expected to initiate Phase 2 development in the second half of 2018.
Financial position and results
| Metric | Q1 2018 | Q1 2017 | Change |
|---|---|---|---|
| License and collaboration revenue | $10.8 million | $0 | New revenue source |
| Research and development expense | $15.4 million | $11.3 million | Up 36% |
| General and administrative expense | $3.6 million | $3.0 million | Up 22% |
| Total operating expenses | $19.0 million | $14.3 million | Up 33% |
| Loss from operations | $8.2 million loss | $14.3 million loss | Improved by $6.0 million |
| Interest income | $0.6 million | $0.2 million | Up $0.4 million |
| Net loss | $7.7 million | $14.1 million | Improved by $6.4 million |
| Basic and diluted loss per share | $0.36 | $0.84 | Improved |
| Net cash used in operating activities | $15.1 million | $10.4 million | Use increased |
Q1 2018 revenue primarily reflected $10.5 million recognized from the Janssen agreement based on proportional performance and $0.3 million for other Phase 2-related services. Deferred revenue declined to $21.9 million from $31.8 million at December 31, 2017.
- Cash, cash equivalents and available-for-sale securities totaled $140.5 million at March 31, 2018, compared with $155.5 million at December 31, 2017.
- Cash and cash equivalents were $69.6 million; available-for-sale securities were $70.9 million, including $5.6 million classified as noncurrent.
- Total assets were $149.2 million and total liabilities were $34.6 million. Stockholders’ equity was $114.6 million.
- Accumulated deficit was $109.2 million.
- The company reported no outstanding debt and no credit facility.
- Cash used in investing activities was $21.8 million, principally from purchases of marketable securities. Financing activities provided $0.5 million from employee equity transactions.
- Operating lease obligations totaled $12.6 million, with a $0.45 million letter of credit collateralized by restricted cash.
Material changes versus the prior comparable period
- Revenue increased from zero to $10.8 million because the Janssen collaboration became effective in 2017 and revenue was recognized as performance obligations were satisfied.
- Research and development spending increased $4.1 million, driven by higher PTG-100, PTG-200 and PTG-300 clinical-development costs and increased personnel. These increases were partly offset by lower discovery spending and higher grant and tax-incentive reimbursements.
- PTG-100 clinical and development expense was $9.1 million, PTG-200 expense was $3.2 million and PTG-300 expense was $2.6 million.
- General and administrative expense rose $0.7 million, primarily due to personnel, business taxes and consulting costs.
- Despite higher operating expenses and operating cash use, the Janssen revenue and increased interest income reduced the net loss substantially.
- Cash and investments declined by approximately $15.0 million from year-end 2017, primarily reflecting operating cash use and investment purchases.
Guidance, outlook, commentary and risks
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund anticipated operating and capital requirements for at least the next 12 months, based on the current operating plan.
- The company expects continuing operating losses and stated that substantial additional capital will be required to complete clinical development and potentially commercialize its candidates.
- The company may raise capital through equity, debt, collaborations or other arrangements. Its effective shelf registration permitted up to $200.0 million of offerings, with up to $50.0 million available through an at-the-market facility; no shares had been sold under that facility as of the filing.
- Under the Janssen agreement, the company received a $50.0 million upfront payment and may receive future opt-in, development, regulatory and sales milestones, as well as royalties. Future payments remain contingent on clinical, regulatory, commercial and Janssen election outcomes.
- The Janssen agreement’s transaction price included $53.9 million as of March 31, 2018. The potential $25.0 million IND-filing payment remained fully constrained, and no milestone or royalty revenue had been recognized.
- Janssen may terminate the agreement for convenience. If the collaboration ends, rights generally revert to Protagonist, but the company could be required to fund additional development and manufacturing activities itself.
- Key risks include the failed interim efficacy assessment for PTG-100, clinical and regulatory uncertainty for PTG-200 and PTG-300, reliance on Janssen and third-party manufacturers and clinical research organizations, possible need for future financing, intellectual-property challenges, competition, and potential dilution from future equity offerings.
- A patent-infringement lawsuit relating to PTG-200 was dismissed without prejudice in February 2018; no amended complaint or appeal was filed, and the matter was concluded as of the filing.
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level, with no material changes in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether PTG-200 advances successfully through Phase 1 and whether Janssen makes the applicable Phase 2 opt-in election.
- The timing and probability of the expected second-half 2018 IND and regulatory filings for PTG-200 and PTG-300.
- The company’s cash runway after the PTG-100 discontinuation and the planned PTG-200, PTG-300 and discovery programs.
- The assumptions and cost estimates supporting recognition of Janssen collaboration revenue and the remaining $21.9 million deferred-revenue balance.
- Whether additional financing is required and the potential dilution or other terms of such financing.
- Results of the company’s review of the complete PTG-100 Phase 2b dataset and any decision regarding further development.
- The continuing status of intellectual-property rights and any future litigation involving PTG-200 or other candidates.